



Generali Employee Benefits Network

#WeSpeakYourLanguage

Giugno 2021



GENERALI
Employee Benefits Network

01

La nostra presenza e la nostra visione

Costruire insieme un futuro sostenibile.



Generali Employee Benefits (GEB) Network

Innovazione e leadership: risultati integrati del 2020




Un unico Team per un servizio globale

203 persone, 3 hub regionali e 12 uffici



Proteggere i vostri valori, ovunque vi troviate.

Siamo presenti in 123 Paesi a livello globale, insieme ai nostri 139 Partner di rete



■ Copertura della rete GEB

Partner della rete GEB

- ✓ assicuratori locali
- ✓ **ai primi posti** nel loro mercato
- ✓ apprezzati per la loro **straordinaria esperienza e i servizi di alta qualità**
- ✓ specialisti nel settore dei benefit per i dipendenti.

La nostra missione: concentrarci sul vostro percorso

Abbiamo tutti gli elementi distintivi per essere Partner di Vita.



Un unico punto di contatto

Attraverso i nostri Team dedicati, offrendo una Governance potenziata e semplificazione nei processi



Un approccio globale

che garantisca coerenza e reattività su tutto il nostro Network



Una visione tecnica e innovativa

necessaria per rispondere alle mutevoli esigenze dei nostri clienti



Condivisione di dati e informazioni


offrendo servizi ad alto valore aggiunto ed un sistema di partnership diffuso

Specializzati nel supportare aziende multinazionali

02

Le nostre soluzioni e i nostri servizi

Proteggere le vostre Persone, insieme.



Le nostre soluzioni

Noi ci occupiamo del rischio mentre voi migliorate la vostra governance.

LifeCycle Pooling

Globale

E' la soluzione per le multinazionali che vogliono gestire con efficacia la loro strategia globale di Employee Benefits. Il Pool consente di raggruppare le coperture Employee Benefits delle filiali in tutto il mondo in un unico conto centralizzato, con una soluzione che si adatta alle dimensioni ed al profilo di rischio del Cliente ed alla sua evoluzione nel tempo.

Captive

Globale

Una società captive è una compagnia assicurativa (ri)creata esclusivamente per assicurare o riassicurare i rischi del gruppo a cui appartiene. Rappresenta un approccio strategico alla gestione dei piani di benefits assicurati di una società e offre modi interessanti per governare, finanziare e fornire pacchetti di benefits per i dipendenti competitivi, con piena trasparenza e controllo.

Global Underwriting Program

Globale

Questa soluzione si basa su una strategia di finanziamento proattiva e comprende una definizione in via anticipata di termini e condizioni, migliorate e negoziate a livello centrale, nonché tassi garantiti e ottimizzazione delle variabili di costo presenti nell'intero programma in base ad analisi per Paese e per copertura.

Protezione Locale

Locale


Agiamo a stretto contatto con i nostri Partners locali nella scelta dei servizi e delle coperture da offrire alle multinazionali e alle loro filiali, beneficiando delle loro esperienza e delle loro capacità assuntive.

Servizi per la salute e il benessere (H&W)

Un Team dedicato, strumenti digitali interattivi e Partnerships di alto profilo

Global medical claim dashboard

I report interattivi forniscono una panoramica dell'esperienza sinistri per paese e identificano le tendenze chiave e i driver di costo aiutando gli utenti nel monitoraggio dei piani sanitari. I report sono disponibili per 40 paesi e concorrono a coprire il 90% del portafoglio GEB.



Health Resource Center

GEB offre l'accesso a una gamma di contenuti, strumenti digitali e servizi disponibili a livello globale/centrale, sostenendo il benessere dei dipendenti in tutto il mondo.


- Multimedia health kits:** Help your employees manage and prevent illness with our multimedia health kits.
- Digital health services:** Tools and services to support employee health.
- Country health profiles:** Local country health trends and GEB network partner medical capabilities.
- Podcasts & webinars:** Learn about emerging medical trends & new perspectives on global care.
- Health & wellbeing news:** Find articles on benefits, management, and health & wellbeing news.
- Medical reports:** Learn more about GEB's interactive medical dashboard reports.

Client Data Centre

Accesso immediato per Clienti e Broker a dati, reports e dashboards 24/7


Unico punto di accesso

- ✓ Online dashboard con dati storici dei programmi attivi
- ✓ Panoramica a livello Globale e locale
- ✓ Aggiornamenti trimestrali
- ✓ Strumento altamente interattivo
- ✓ Possibilità di fare il download dei dati.




Centro risorse COVID-19

Tutte le informazioni sono accessibili su geb.com/COVID-19.



- COVID-19 resources on GEB.com
- Updated on an ongoing basis
- Links to global health resources including WHO dynamic maps, public health sites
- Network partner T&Cs pertaining to Covid-19
- Region-specific detail including local health updates, ministry of health announcements, announcements from local hospital authorities



OUR CONTACTS & LOCATIONS

COVID-19

Being a Generali Partner to our clients is for us of the utmost importance and, today more than ever, it means building trust and giving them the assurance, with the outbreak of the Covid-19 epidemic, we have immediately taken action to make sure you are informed as to what we are doing as a Network for you and your employees.

This section is intended to be **informative** and **your practical advice** on COVID-19 **not for enable employees and multinational companies** at your works.

Generali Network is highly committed to sharing **updated information** on local practices of managing COVID-19 outbreak and actively supporting insureds.

Find in the dedicated pages how GEB Network is responding to COVID-19 locally and which services are available for your employees.

For further questions, please contact info@geb.com
[More updated by the World Health Organization](#)

World Health Organization
WHO Coronavirus Disease (COVID-19) Dashboard
Data last updated: 2020/05/28 17:30:00 UTC

194,917	5,704,736	357,736
new cases	confirmed cases	deaths

Globaly, as of 7:00pm CEST, 28 May 2020, there have been 5,704,736 confirmed cases of COVID-19, including 357,736 deaths, reported to WHO.

GEB Network supporting materials and useful links

- **Remove advice on COVID-19 for mobile employees** - [28 May 2020 by Euro Assistance](#)
Regular update on medical information and action recommendations regarding the COVID-19 epidemic.
- **Information and updates by the World Health Organization**
World Health Organization website dedicated to the COVID-19 outbreak with situation reports, travel advice, medical recommendations and an updated world map with the spread of COVID-19.
- **COVID-19 outbreak updates by Centers for Disease Control and Prevention**
Centers for Disease Control and Prevention website dedicated to the COVID-19 outbreak with useful tips on how to protect ourselves and to spot the symptoms. Recently used questions, travel advice and travel tips.



COVID-19 Health Bulletin

Keeping safe

Simple steps for you and your family

Following is information drawn from public health sources on how to protect yourself and others from the COVID-19 virus.

Since there is no vaccine or drug therapy currently available, avoiding exposure and preventing spread are the best ways to keep everyone safe. Here are 6 steps you can take immediately to avoid exposure and prevent spread:

- 1** Maintain your social distance from others. If you have to go out for essential activities, keep at least 2 meters (approximately 6 feet) between yourself and others to prevent inhalation of droplets that can be shared by talking, sneezing or coughing.
- 2** Wash your hands with soap and water for at least 20 seconds. After this, use an alcohol-based hand sanitizer to continue to protect your hands from virus.
- 3** Avoid touching your eyes, nose, and mouth all of which are potential points of entry for the virus.
- 4** Practice good respiratory hygiene by coughing or sneezing into your bent elbow or a tissue; dispose of the tissue immediately in a sealed trash bin.
- 5** If you develop symptoms seek medical advice but call your doctor first. Calling your doctor or contacting a telemedicine provider if this is available to you will allow the health-care professional to direct you to an appropriate facility and help to prevent further spread of the virus.
- 6** Know when and how to wear a mask. Do wear a mask if you're coughing or sneezing, or if you're helping to care for someone who is sick.

Keep informed and up to date by following instructions and guidance from the WHO, the CDC, your local government and health authorities.

GENERALI
Employee Benefits Network

Source: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/faq-questions>, <https://www.cdc.gov/covid19/about-the-disease.html>, <https://www.cdc.gov/covid19/about-the-disease.html> (2) Website for legal

Bollettino sul vaccino COVID-19

Scopri di più su geb.com/COVID-19.

GEB fornisce un dossier informativo sui vaccini contro il COVID-19 aggiornato su base mensile e sviluppato in collaborazione con Granite Management, che fornisce:

- ✓ Aggiornamenti sulle varianti del virus
- ✓ Aggiornamenti sui vaccini approvati e su quelli nelle sperimentazioni cliniche di fase 3
- ✓ Impatto sui datori di lavoro e quali le azioni possibili.

COVID-19 Vaccine Update
February 2021

Continuing our research and product development, Generali Employee Benefits and Granite Management Limited (GML) have worked in collaboration to develop the latest information offering perspectives on available data related to COVID-19 vaccine development, and some suggested implications for our members. We hope this provides you with an understanding of the most relevant vaccine candidates, their status, approval and delivery plans for future use, as well as the health impact of your employees, and what you can do to support them.

February Updates

Growing threat of COVID variants

The variant appears to include mutations that are causing more illness in those that have been vaccinated. This is a concerning development, as it suggests that the vaccine may not be as effective as initially thought. The variant is spreading rapidly in the UK, South Korea and Brazil, and new variants are being identified in the US.

The variant appears to include mutations that are causing more illness in those that have been vaccinated. This is a concerning development, as it suggests that the vaccine may not be as effective as initially thought. The variant is spreading rapidly in the UK, South Korea and Brazil, and new variants are being identified in the US.

There are concerns that the vaccine currently approved may not be as effective against all of the new variants. Further research is being conducted to assess the effectiveness of the vaccine against these new variants. It is also being investigated whether the vaccine can be updated to target these new variants. This will involve making changes to the structure of the vaccine.

It is now believed that COVID-19 is here to stay and will continue to be a global health issue for the foreseeable future. While it is not yet clear how long it will take for the world to return to normal, it is likely that the current vaccine will be able to protect against the virus for a significant period of time. However, it is important to continue to monitor the situation and be prepared to respond to any changes in the virus.

Emerging variants and notable mutations

Following a high level of awareness, our members should be aware of the latest developments in the COVID-19 vaccine. The following table provides an overview of the current status of the vaccine, including the number of countries where it is being used, the number of people who have received it, and the number of people who have been vaccinated.

B.1.1.7 Variant (first identified in UK)

- Identified in 16 countries, extended to 30. 50% of new infections in the UK are due to this variant.
- Vaccine efficacy: There is a growing concern over vaccine efficacy. There is a growing concern over vaccine efficacy. There is a growing concern over vaccine efficacy.

B.1.351 Variant (first identified in South Africa)

- Identified in 12 countries and is becoming the dominant variant in South Africa. It is also being identified in other parts of the world.
- Vaccine efficacy: There is a growing concern over vaccine efficacy. There is a growing concern over vaccine efficacy. There is a growing concern over vaccine efficacy.

P.1 Variant (first identified in Brazil)

- Identified in 12 countries and is becoming the dominant variant in Brazil. It is also being identified in other parts of the world.
- Vaccine efficacy: There is a growing concern over vaccine efficacy. There is a growing concern over vaccine efficacy. There is a growing concern over vaccine efficacy.

Vaccine rollout across the globe

Vaccine rollout continues to proceed rapidly across the globe. As of February 2021, over 100 million people have received a COVID-19 vaccine. The rollout is expected to continue to accelerate over the next few months. The following table provides an overview of the current status of the vaccine, including the number of countries where it is being used, the number of people who have received it, and the number of people who have been vaccinated.

% Population vaccinated by country		
Country	Numbered	Percentage
USA	22.2%	22.2%
Spain	20.7%	20.7%
Germany	19.7%	19.7%
France	19.7%	19.7%
Italy	19.7%	19.7%
UK	19.7%	19.7%
Canada	19.7%	19.7%
Japan	19.7%	19.7%
South Korea	19.7%	19.7%
India	19.7%	19.7%
China	19.7%	19.7%
Italy	19.7%	19.7%
Spain	19.7%	19.7%
Germany	19.7%	19.7%
France	19.7%	19.7%
UK	19.7%	19.7%
Canada	19.7%	19.7%
Japan	19.7%	19.7%
South Korea	19.7%	19.7%
India	19.7%	19.7%
China	19.7%	19.7%

Summary of approved vaccines

Vaccine name	Companies
AZD-1222 (AstraZeneca)	<ul style="list-style-type: none"> • AstraZeneca (UK), AstraZeneca (Spain), AstraZeneca (Germany), AstraZeneca (France), AstraZeneca (Italy), AstraZeneca (Japan), AstraZeneca (South Korea), AstraZeneca (India), AstraZeneca (China), AstraZeneca (Brazil), AstraZeneca (Mexico), AstraZeneca (Canada), AstraZeneca (Australia), AstraZeneca (New Zealand), AstraZeneca (Singapore), AstraZeneca (Taiwan), AstraZeneca (Thailand), AstraZeneca (Vietnam), AstraZeneca (Indonesia), AstraZeneca (Philippines), AstraZeneca (Malaysia), AstraZeneca (Vietnam), AstraZeneca (Thailand), AstraZeneca (Indonesia), AstraZeneca (Philippines), AstraZeneca (Malaysia)
BBV-152 (BioCruc)	<ul style="list-style-type: none"> • AstraZeneca (UK), AstraZeneca (Spain), AstraZeneca (Germany), AstraZeneca (France), AstraZeneca (Italy), AstraZeneca (Japan), AstraZeneca (South Korea), AstraZeneca (India), AstraZeneca (China), AstraZeneca (Brazil), AstraZeneca (Mexico), AstraZeneca (Canada), AstraZeneca (Australia), AstraZeneca (New Zealand), AstraZeneca (Singapore), AstraZeneca (Taiwan), AstraZeneca (Thailand), AstraZeneca (Indonesia), AstraZeneca (Philippines), AstraZeneca (Malaysia), AstraZeneca (Vietnam), AstraZeneca (Thailand), AstraZeneca (Indonesia), AstraZeneca (Philippines), AstraZeneca (Malaysia)
CoronaVac (Sinovac)	<ul style="list-style-type: none"> • AstraZeneca (UK), AstraZeneca (Spain), AstraZeneca (Germany), AstraZeneca (France), AstraZeneca (Italy), AstraZeneca (Japan), AstraZeneca (South Korea), AstraZeneca (India), AstraZeneca (China), AstraZeneca (Brazil), AstraZeneca (Mexico), AstraZeneca (Canada), AstraZeneca (Australia), AstraZeneca (New Zealand), AstraZeneca (Singapore), AstraZeneca (Taiwan), AstraZeneca (Thailand), AstraZeneca (Indonesia), AstraZeneca (Philippines), AstraZeneca (Malaysia), AstraZeneca (Vietnam), AstraZeneca (Thailand), AstraZeneca (Indonesia), AstraZeneca (Philippines), AstraZeneca (Malaysia)
Novavax (Novavax)	<ul style="list-style-type: none"> • AstraZeneca (UK), AstraZeneca (Spain), AstraZeneca (Germany), AstraZeneca (France), AstraZeneca (Italy), AstraZeneca (Japan), AstraZeneca (South Korea), AstraZeneca (India), AstraZeneca (China), AstraZeneca (Brazil), AstraZeneca (Mexico), AstraZeneca (Canada), AstraZeneca (Australia), AstraZeneca (New Zealand), AstraZeneca (Singapore), AstraZeneca (Taiwan), AstraZeneca (Thailand), AstraZeneca (Indonesia), AstraZeneca (Philippines), AstraZeneca (Malaysia), AstraZeneca (Vietnam), AstraZeneca (Thailand), AstraZeneca (Indonesia), AstraZeneca (Philippines), AstraZeneca (Malaysia)
Moderna (Moderna)	<ul style="list-style-type: none"> • AstraZeneca (UK), AstraZeneca (Spain), AstraZeneca (Germany), AstraZeneca (France), AstraZeneca (Italy), AstraZeneca (Japan), AstraZeneca (South Korea), AstraZeneca (India), AstraZeneca (China), AstraZeneca (Brazil), AstraZeneca (Mexico), AstraZeneca (Canada), AstraZeneca (Australia), AstraZeneca (New Zealand), AstraZeneca (Singapore), AstraZeneca (Taiwan), AstraZeneca (Thailand), AstraZeneca (Indonesia), AstraZeneca (Philippines), AstraZeneca (Malaysia), AstraZeneca (Vietnam), AstraZeneca (Thailand), AstraZeneca (Indonesia), AstraZeneca (Philippines), AstraZeneca (Malaysia)
Pfizer (Pfizer)	<ul style="list-style-type: none"> • AstraZeneca (UK), AstraZeneca (Spain), AstraZeneca (Germany), AstraZeneca (France), AstraZeneca (Italy), AstraZeneca (Japan), AstraZeneca (South Korea), AstraZeneca (India), AstraZeneca (China), AstraZeneca (Brazil), AstraZeneca (Mexico), AstraZeneca (Canada), AstraZeneca (Australia), AstraZeneca (New Zealand), AstraZeneca (Singapore), AstraZeneca (Taiwan), AstraZeneca (Thailand), AstraZeneca (Indonesia), AstraZeneca (Philippines), AstraZeneca (Malaysia), AstraZeneca (Vietnam), AstraZeneca (Thailand), AstraZeneca (Indonesia), AstraZeneca (Philippines), AstraZeneca (Malaysia)



Aggiornamento trimestrale su Partnerhips, soluzioni e servizi

Registrati su geb.com per accedere a tutte le novità per i nostri clienti e intermediari.

GEB Insights

geb.com | [social icons]

GENERALI Employee Benefits Network

Local Protection Global Connection

GEB CLIENT INSIGHTS 01 | 2020

In this issue

- **COVID-19**
[sub-points]
- **Network Partners**
[sub-points]
- **Global Programmes & Must Reads**
[sub-points]
- **Services & Tools**
[sub-points]
- **Health & Wellbeing**
[sub-points]
- **Events & Conferences**
[sub-points]
- **People**
[sub-points]
- **Regional Office Contacts**
[sub-points]

2

Argomenti

GEB INTERMEDIARY INSIGHTS 01 | 2020

Services & Tools

GEB Client Data Center

- Access their historical data
- Download their selection of data
- Customise data view according to their needs
- Access to our benchmark data, comparing their data results to those of the GEB overall portfolio
- Analyse additional KPIs to obtain ratio comparison over 3 years

Watch the video to find out more [here](#)

DocuSign

GEB obtains ISAE 3402 Certifications

ISAE 3402 was developed by the International Auditing and Assurance Standards Board. It puts more emphasis on procedures for the ongoing monitoring and evaluation of controls. This certification allows GEB to have its control and controls (GEBIS Data Center) have carefully documented the processes, created controls for each of them, and gathered sufficient evidence to demonstrate to our auditors that our controls are in place AND work efficiently and effectively.

ISAE 3402 was developed by the International Auditing and Assurance Standards Board. It puts more emphasis on procedures for the ongoing monitoring and evaluation of controls. This certification allows GEB to have its control and controls (GEBIS Data Center) have carefully documented the processes, created controls for each of them, and gathered sufficient evidence to demonstrate to our auditors that our controls are in place AND work efficiently and effectively.

ISAE 3402 was developed by the International Auditing and Assurance Standards Board. It puts more emphasis on procedures for the ongoing monitoring and evaluation of controls. This certification allows GEB to have its control and controls (GEBIS Data Center) have carefully documented the processes, created controls for each of them, and gathered sufficient evidence to demonstrate to our auditors that our controls are in place AND work efficiently and effectively.

ISAE 3402
Certified Type 1

5

Video

GEB INTERMEDIARY INSIGHTS 01 | 2020

Global Programmes

Global Underwriting Programme

Earlier Year-end closing 2019 for Caplives

Thanks to the cooperation and support of all Network Partners, GEB was able to deliver year-end 2019 insurance data earlier than promised. Instead, the valuable support of our Network allowed us to get 98% of the data in 141 hours out of 162 hours completed. Compared to last year, 32% more data served without delay, of which 80% was even received in advance of the deadline.

GUIP Brochure

The new brochure about Global Underwriting Programme is now available [here](#)

The main elements are:

- What is a Global Underwriting Programme (GUIP)?
- The three basic principles of a GUIP
- Key elements for the successful roll-out
- How does the optimisation work?
- Who assumes the risk of the GUIP?
- What are the minimum requirements to set up a GUIP?

MUST READS

- **Caplives Review:** Global Medical, a critical component of the global benefits strategy by **Eric Butler**
- **Caplives Insurance Times:** a whole lot's also by **Fred Van den Ende** and **Viktor Zamboni**
- **Caplives Insurance Times:** Analyzing Women by **Daniela Mauerer**
- **Caplives Review:** Power 50, interview with **Andrea Vascotto** and **Lara Tiberto**
- **Caplives Insurance Times:** Caplives and workplace wellness programmes. Drawing the debate by **Marc Reinhardt**
- **Commercial Risk:** Trends in workplace benefit cost drivers by **Pablo Ribera**

JUST CLICK

7

Articoli

Grazie. Non vediamo l'ora
di iniziare il nostro Viaggio Insieme.

Marketing & Customer Experience

Contattaci all'indirizzo MandCE@geb.com



Scopri di più su geb.com

#WeSpeakYourLanguage

Esclusione di responsabilità

“Queste informazioni e comunicazioni sono fornite da Assicurazioni Generali S.p.A. – Filiale del Lussemburgo (“La Società”), con sede legale in 52, boulevard Marcel Cahen, L-1311 Lussemburgo, Granducato del Lussemburgo. Assicurazioni Generali S.p.A. – Filiale del Lussemburgo è la filiale lussemburghese di Generali Assicurazioni S.p.A., una società per azioni di diritto italiano, con sede legale in 34132 Trieste, piazza Duca degli Abruzzi, 2 e costituita con il numero 00079760328. Utilizzando o scaricando questa Pubblicazione, l'utente accetta i Termini e le Condizioni qui di seguito stabiliti e verrà considerato ad esse vincolato.

I contenuti di questa Pubblicazione sono di proprietà della Società. Tutti i diritti sono riservati alla Società. I contenuti di questa Pubblicazione non possono essere copiati, riprodotti, trasferiti, caricati, pubblicati o distribuiti in alcun modo, in tutto o in parte, senza il previo consenso scritto della Società, ad eccezione del fatto che la Società consente di stampare degli estratti di queste pagine esclusivamente per uso personale. I marchi e i loghi visualizzati che compaiono in questa Pubblicazione sono di proprietà della Società e delle sue controllate (Generali Group) o dei rispettivi proprietari e non possono essere utilizzati senza il previo consenso scritto della Società.

Le informazioni contenute in questa Pubblicazione sono fornite in buona fede dalla Società, che le ritiene accurate. La presente Pubblicazione non è intesa a coprire ogni aspetto degli argomenti dei benefit citati e la Società non ne garantisce la completezza o l'accuratezza. La presente Pubblicazione non è concepita per fornire consulenza legale o di altro tipo e i lettori devono rivolgersi a consulenti legali o finanziari per avere assistenza in materia legale o di benefit internazionali. Le informazioni contenute in questa Pubblicazione sono prodotte da fonti sia interne che esterne. La Società si riserva il diritto di modificare tali informazioni e le specifiche di utilizzo funzionale e operativo applicabili alla Pubblicazione come e quando sceglierà di farlo, a sua discrezione e senza preavviso. La Società farà il possibile per garantire che le informazioni presentate nella Pubblicazione siano pienamente conformi ai requisiti di affidabilità, veridicità e accuratezza. Tuttavia, la Società non si assume alcuna responsabilità per eventuali errori o imprecisioni nel contenuto della Pubblicazione derivanti da circostanze che non possono esserle attribuite. La Società non si assume alcuna responsabilità per l'affidabilità, l'accuratezza e la veridicità delle informazioni contenute nella Pubblicazione che non possono esserle attribuite. Inoltre, la Società non si assume alcuna responsabilità per le eventuali conseguenze indesiderate di interruzioni, ritardi o disfunzioni, brevi o prolungati, nella fornitura del servizio di Pubblicazione a causa di circostanze al di fuori del suo controllo. Nessuna delle informazioni contenute nei siti web collegati costituisce una raccomandazione, una sollecitazione o un'offerta da parte della Società o delle sue affiliate per acquistare o vendere titoli o altri strumenti finanziari o fornire consigli o servizi di investimento; alcune informazioni possono essere trovate sui siti web collegati poiché la loro pubblicazione è richiesta o raccomandata dalla legge, dalle normative o dalle disposizioni dei codici di autoregolamentazione. Le informazioni contenute in questa Pubblicazione non possono essere utilizzate, scaricate o importate all'estero o da persone straniere, laddove la fornitura, l'uso, la comunicazione o la diffusione delle stesse siano contrari alle leggi, alle norme o ai regolamenti applicabili di qualsiasi autorità governativa o organizzazione regolamentare o di autoregolamentazione o laddove la Società non sia autorizzata a fornire tali informazioni o servizi. Tali informazioni non costituiscono o fanno parte di e non devono essere interpretate come un'offerta da parte o per conto della Società o come invito a sottoscrivere o acquistare titoli in alcun Paese, ivi inclusi, a titolo esemplificativo ma non esaustivo, gli Stati Uniti d'America, o a qualsiasi “Persona statunitense”, come definito nel “Regolamento S” ai sensi della Legge sui valori mobiliari del 1933 degli Stati Uniti (Securities Act), come successivamente emendato”.